<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="847">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04552951</url>
  </required_header>
  <id_info>
    <org_study_id>2020-019-PF-CAANJ</org_study_id>
    <nct_id>NCT04552951</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin D on Morbidity and Mortality of the COVID-19</brief_title>
  <acronym>COVID-VIT-D</acronym>
  <official_title>Estudio Destinado a Valorar la Utilidad de Vitamina D Sobre Morbilidad y Mortalidad de la infección Por Virus SARS-COV-2 (COVID-19) en el Hospital Universitario Central de Asturias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación para la Investigación Biosanitaria del Principado de Asturias</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario Central de Asturias</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Investigación Sanitaria del Principado de Asturias</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación para la Investigación Biosanitaria del Principado de Asturias</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients diagnosed of COVID-19 disease are randomized to receive a single dose of 100.000 IU
      of Cholecalciferol (Vitamin D arm) or no vitamin D (on top of the current medication used to
      treat COVID 19).

      Clinical, radiological and biochemical outcomes of COVID 19 disease as well as mortality are
      evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy parameters to compare both groups (vitamin D and No vitamin D).

      Time to reach undetectable levels of SARS COV2 Infection.

      Time of normalization of symptoms and clinical parameters.

      Time of normalization of radiological images.

      Time of normalization of biochemical markers.

      Time of normalization of molecular inflammatory markers.

      Transfer to the Intensive care Unit.

      Mortality rate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 14, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients receiving any form. of vitamin D excluded from the study. Randomized study (Initial serum calcidiol levels blinded )</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Time to death or hospital discharge in days (average 12 days)</time_frame>
    <description>Percentage of patients dying during hospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Admission to Intensive Care Unit (ICU)</measure>
    <time_frame>Time from hospital admission to discharge in days (average 12 days)</time_frame>
    <description>Percentage of patients admitted to ICU and time in ICU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of hospitalization</measure>
    <time_frame>Time of hospitalization in days (average 12 days)</time_frame>
    <description>Number of days from hospital admission to discharge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical changes</measure>
    <time_frame>At the time of hospital admission and discharge (average 12 days)</time_frame>
    <description>Percentage of patients with symptoms after treatment (Cough, fever, headache, weakness, dyspnoea, anosmia, diarrhoea, ageusia, others ...)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiological changes</measure>
    <time_frame>At the time of hospital admission and discharge (average 12 days)</time_frame>
    <description>Changes in the percentage of patients with radiological findings of pneumonia and severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calcidiol changes</measure>
    <time_frame>At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)</time_frame>
    <description>Calcidiol levels in ng/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammation markers changes (CRP)</measure>
    <time_frame>At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)</time_frame>
    <description>C-reactive protein (CRP) in mg/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammation markers changes (IL-6)</measure>
    <time_frame>At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)</time_frame>
    <description>Interleukin-6 (IL-6) in pg/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammation markers changes (Leucocytes)</measure>
    <time_frame>At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)</time_frame>
    <description>Leucocytes in cells per liter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammation markers changes (D-dimer)</measure>
    <time_frame>At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)</time_frame>
    <description>D-dimer in µg/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>General biochemical parameters changes (Creatinine)</measure>
    <time_frame>At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)</time_frame>
    <description>Creatinine in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>General biochemical parameters changes (Ferritin)</measure>
    <time_frame>At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)</time_frame>
    <description>Ferritin in µg/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>General biochemical parameters changes (Bilirubin)</measure>
    <time_frame>At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)</time_frame>
    <description>Bilirubin in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>General biochemical parameters changes (Albumin)</measure>
    <time_frame>At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)</time_frame>
    <description>Albumin in g/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>General biochemical parameters changes (Haemoglobin)</measure>
    <time_frame>At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)</time_frame>
    <description>Haemoglobin in g/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>General biochemical parameters changes (HDL cholesterol)</measure>
    <time_frame>At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)</time_frame>
    <description>High density lipoprotein (HDL cholesterol) in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>General biochemical parameters changes (Procalcitonin)</measure>
    <time_frame>At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)</time_frame>
    <description>Procalcitonin in ng/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>General biochemical parameters changes (Protonin)</measure>
    <time_frame>At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)</time_frame>
    <description>Protonin in ng/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>General biochemical parameters changes (Calcium)</measure>
    <time_frame>At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)</time_frame>
    <description>Calcium in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>General biochemical parameters changes (Phosphate)</measure>
    <time_frame>At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)</time_frame>
    <description>Phosphate in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>General biochemical parameters changes (pO2)</measure>
    <time_frame>At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)</time_frame>
    <description>pO2 in mmHg</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receiving 1 dose of 100.000 iu of Cholecalciferol when the COVID 19 Disease is diagnosed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No vitamin D</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Single doe of 100.000 IU</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>Vitamin D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 year

          -  Diagnosis of COVID-19

          -  Accept to participate in the study ( consent)

        Exclusion Criteria:

          -  Pregnancy

          -  Allergy to vitamin D

          -  Consumption of any form of vitamin D during the last 3 months

          -  Expected fatal outcome in the next 24 hours

          -  Cognitive deterioration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jorge B Cannata-Andía, MD PhD</last_name>
    <phone>*34 985 106137</phone>
    <email>cannata@hca.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juan Pérez-Ortega</last_name>
    <phone>*34 985109905</phone>
    <email>juan.perez@finba.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge B Cannata-Andía, MD PhD</last_name>
      <phone>*34 985106137</phone>
      <email>cannata@hca.es</email>
    </contact>
    <contact_backup>
      <last_name>Juan Pérez-Ortega</last_name>
      <phone>*34 985 109905</phone>
      <email>juan.perez@finba.es</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2020</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

